Given its crucial role in cancer metabolism, ACC has emerged as a potential therapeutic target. Inhibitors of ACC, such as TOFA (5-(Tetradecyloxy)-2-furoic acid) and CP-640186, have shown promise in preclinical studies by reducing fatty acid synthesis and triggering apoptosis in cancer cells. Pharmaceutical companies are actively exploring ACC inhibitors as potential treatments for various cancers.
